Lilly stops development of diabetes treatment
Dec 4 (Reuters) - Eli Lilly & Co said it stopped developing its experimental diabetes treatment after discussions with regulatory authorities and external experts.
Lilly had delayed a marketing application for basal insulin peglispro after studies reported an increase in liver fat in patients who were given the treatment.
(Reporting by Vidya L Nathan in Bengaluru; Editing by Don Sebastian)